Lijnen P, Staessen J, Fagard R, Amery A
Clin Exp Hypertens A. 1983;5(2):285-95. doi: 10.3109/10641968309048827.
In a double-blind cross-over trial 15 captopril (daily dose 600 mg) treated patients, received in addition to the converting-enzyme inhibitor, placebo or bendrofluazide (7.5 mg). Bendrofluazide lowered blood pressure, while body weight decreased slightly. During captopril-bendrofluazide treatment, the plasma renin-angiotensin-aldosterone system was stimulated, while no effect on the urinary excretion of prostaglandin E2 and F2 alpha was found.